drugset / Trial / NCT00664391

Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Breeze

NCT00664391

Phase 3 Completed 32 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelSupportive care

Summary

The purpose of this study is to demonstrate the safety of the gynecological formulation in normal and usual usage condition of Dermacyd Breeze.

Timeline

Start
2008-01
Primary completion
2008-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactic Acid Other / unclassified Topical

Indications

No indication recorded.